Ablynx NV – “Nanobodies – Still Worth a Risk”
Pfizer’s returning of rights to the advanced anti-TNF (Ozoralizumab, ATN-103, PhIIb, RA) nanobody program to Ablynx (ABLX) has shaken investor’s confidence in the company. Outcome of the upcoming milestone (ALX-0081, PhII, anti-von Willebrand factor, Intravenous formulation data in ACS) is binary in nature. ABLX has established collaborations with major pharma companies for its technology platform. Ablynx is currently trading close to its cash value and could be a good target….. For more details, please read our report released on 9th November, 2011 on ABLX titled “Nanobodies – Still Worth a Risk!”
COMPANIES MENTIONED
Ablynx NV
Ablynx NV
